medigraphic.com
ISSN 1561-2988 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Farm 2022; 55 (2)

Regulation for Haemophilus influenzae type b conjugate vaccines, based on synthetic oligosaccharides

Rodríguez SA, Sánchez GCA, Hardy RE

Language: Spanish
References: 35
Page: 1-19
PDF size: 771.38 Kb.


ABSTRACT

Introduction: The World Health Organization plays a decisive role in the regulation of vaccines to ensure their safe use, if their positive health impact is taken into account.
Objective: To demonstrate the current alignment of the Cuban Quimi-Hib® vaccine with the current regulatory framework of the World Health Organization, applicable to this vaccine.
Methods: Descriptive, longitudinal and retrospective study of the information published by the World Health Organization, in force in 2021, of the type of guidelines and trend documents, applicable in a general or particular way. The information was collected by bibliographic search in public sources and organized in tables according to type, year of issuance and content. The current requirements were compared with those available during the development and registration of Quimi-Hib® in Cuba. The evaluation of previous editions and their compliance was included.
Results: 18 documents were identified which were published by WHO between 1992 and 2017, of which 16 were normative and two were trend documents. A total of four were in force in 2003 and of the remaining 14, six had previous editions. Evidence of implementation in the evolution of nine current documents with several editions was related.
Conclusions: The World Health Organization has enacted a comprehensive regulatory framework applicable to conjugate vaccines against Haemophilusinfluenzae type b. Quimi- Hib's® research, development and sanitary registration process followed these recommendations for vaccines of this type based on natural polysaccharides, due to the absence of specific requirements for synthetic oligosaccharides. After its registration in 2003, it has been verified that its alignment with the updates made to this regulatory framework is maintained, in which there are still no specifications for Hib vaccines based on synthetic oligosaccharides.


REFERENCES

  1. Organización Mundial de la Salud. Constitución de la Organización Mundial de la Salud.Documentos Básicos. 48.a edición. OMS 2014, pp. 1-21. Ginebra: OMS. [acceso 22/02/2022]. Disponible en: http://apps.who.int/gb/bd/s/s_index.html

  2. Organización Panamericana de la Salud. Misión, visión y funciones de la OrganizaciónMundial de la Salud y reforma de su constitución. SPP27/8, Rev. 1 (Esp.). Washington,DC.: OPS; 1996.

  3. World Health Organization. Who we are. Geneva: WHO; c2022 [acceso 22/02/2022].Disponible en: https://www.who.int/about/who-we-are/history

  4. Organización Mundial de la Salud. Agenda de Inmunización 2030: Una estrategiamundial para no dejar a nadie atrás. Ginebra: OMS; 2020 [acceso 22/02/2022]. Disponibleen: https://www.who.int/publications/m/item/immunization-agenda-2030-a-globalstrategy-to-leave-no-one-behind

  5. Plotkin S, Orenstein W, Offit P. Vaccines, 5th ed. Philadelphia: Saunders/Elsevier; 2008.

  6. Organización Mundial de la Salud. Reglamentación de vacunas: desarrollo en losorganismos actuales de reglamentación farmacéutica. Ginebra: OMS; 1999 [acceso20/02/2022]. Disponible en: https://apps.who.int/iris/handle/10665/66207

  7. World Health Organization. WHO good manufacturing practices for biological products.Technical Report Series. 2016; No. 999 annex 2. Geneva: WHO; 2016 [acceso09/08/2021]. Disponible en: https://www.who.int/publications/m/item/annex-2-trs-no-999-WHO-gmp-for-b iological-products

  8. Organización Mundial de la Salud, Fondo de las Naciones Unidas para la Infancia, BancoMundial. Vacunas e inmunización: situación mundial, tercera edición. Ginebra: OMS;2010.

  9. World Health Organization. Procedure for assessing the acceptability, in principle, ofvaccines for purchase by United Nations agencies. Technical Report Series. 2013; No. 978annex 6. Geneva: WHO; 2013 [acceso 04/02/2017]. Disponible en:http://www.who.int/biologicals/vaccines/TRS_ 978_Annex_6.pdf?ua=1

  10. 10.World Health Organization. Expert Committee on Biological Standardization. Ginebra:OMS; 2022 [acceso 10/03/2022]. Disponible en: https://www.who.int/groups/expertcommittee-on-biological-standardization

  11. World Health Organization. Prequalified Vaccines. Geneva: WHO; 2021 [acceso03/02/2020]. Disponible en: https://extranet.who.int/pqweb/vaccines/prequalifiedvaccines

  12. Organización Mundial de la Salud. Organización Mundial de la Salud-iris RepositorioInstitucional para Compartir Información. Ginebra: OMS; 2022 [acceso 02/02/2022].Disponible en: https://apps.who.int/iris/

  13. World Health Organization. Guidelines for national authorities on quality assurance forbiological products. Technical Report Series. 1992; No. 822, annex 2. Geneva: WHO; 1992[acceso 12/02/2022]. Disponible en: https://www.who.int/biologicals/publications/trs/areas/biological_products/WHO_TRS_822_A2.pdf

  14. World Health Organization. General requirements for the sterility of biologicalsubstances. Technical Report Series. 1998; No. 872, annex 3. Geneva: WHO; 1998 [acceso01/11/2021]. Disponible en: https://www.who.int/biologicals/publications/trs/areas/vaccines/sterility/WHO_TRS_872_A3.pdf

  15. World Health Organization. Guidelines for the production and quality control ofsynthetic peptide vaccines. Technical Report Series. 1999; No. 889, annex 1. Geneva:WHO; 1999 [acceso 01/11/2021]. Disponible en: https://cdn.who.int/media/docs/defaultsource/biologicals/vaccine-standardization/synthetic-peptide-vaccines/who_trs_889_a1.pdf?sfvrsn=8589ee61_3&down load=t rue

  16. World Health Organization. Recommendations for the production and control ofHaemophilus influenzae type b conjugate vaccines. Technical Report Series. 2000; No. 897annex 1. Geneva: WHO; 2000 [acceso 01/11/2021]. Disponible en:https://www.who.int/publications/m/item/hib-conjugate-vaccines-annex-1-t rs-no-897

  17. World Health Organization. Guidelines on regulatory expectations related to theelimination, reduction or replacement of thiomersal in vaccines. Technical Report Series.2004; No. 926 annex 4. Geneva: WHO; 2004 [acceso 10/01/2020]. Disponible en:https://www.who.int/biologicals/publications/trs/areas/vaccines/thiomersal/Annex%204%20(95-102)TRS926thiomersal.pdf

  18. World Health Organization. WHO guidelines on nonclinical evaluation of vaccines.Technical Report Series. 2005; No. 927 annex 1. Geneva: WHO; 2005 [acceso22/08/2021]. Disponible en: https://www.who.int/publications /m/item/annex1-nonclinical.p31-63

  19. World Health Organization. WHO guidelines on tissue infectivity distribution intransmissible spongiform encephalopathies. Geneva: WHO; 2006 [acceso 12/02/2022].Disponible en: http://www.who.int/bloodproducts/tse/en

  20. World Health Organization. WHO tables on tissue infectivity distribution intransmissible spongiform encephalopathies. Updated 2010. Geneva: WHO; 2010 [acceso12/02/2022]. Disponible en: http://www.who.int/bloodproducts

  21. World Health Organization. The Immunological Basis for Immunization Series.Module 9: Haemophilus influenzae type b. Geneva: WHO; 2007 [acceso 09/08/2021].Disponible en: https://apps.who.int/iris/handle/10665/43799

  22. Organización Mundial de la Salud. Directrices sobre la evaluación de estabilidad de lasvacunas. Serie de Informes Técnicos. 2011; No. 962 anexo 3. Ginebra: OMS; 2011 [acceso 10/01/2022]. Disponible en:https://www.gob.mx/cms/uploads/attachment/file/163169/Annex_3_WHO_TRS_962-3_ES_REV.PDF

  23. World Health Organization. Guidelines for independent lot release of vaccines byregulatory authorities. Technical Report Series. 2013; No. 978 annex 2. Geneva: WHO;2013 [acceso 04/02/2017]. Disponible en:http://www.who.int/biologicals/TRS_978_Annex_2.pdf?ua=1

  24. World Health Organization. Haemophilus influenzae type b (Hib) Vaccination PositionPaper - September 2013. Weekly epidemiol record. 2013 [acceso 10/01/2022];88(39):413-28. Disponible en: https://apps.who.int/iris/handle/ 10665/242126

  25. World Health Organization. Guidelines on the nonclinical evaluation of vaccineadjuvants and adjuvanted vaccines. Technical Report Series. 2014; No. 987 annex 2.Geneva: WHO; 2014 [acceso 15/02/2021]. Disponible en:https://www.who.int/publications/m/item/nonclinical-evaluation-of-vaccine-adjuvantsand-adjuvanted-vaccines-annex-2-trs-no-987

  26. World Health Organization. Scientific principles for regulatory risk evaluation onfinding an adventitious agent in a marketed vaccine. Technical Report Series. 2015; No.993 annex 2. Geneva: WHO; 2015 [acceso 03/04/2021]. Disponible en:https://www.who.int/publications/m/item/adventitious-agent-in-a-marketed-vaccineannex-2-trs-no-993

  27. World Health Organization. Guidelines on procedures and data requirements for changesto approved vaccines. Technical Report Series. 2015; No. 993 annex 4. Geneva: WHO; 2015[acceso 03/04/2021]. Disponible en: https://www.who.int/publications/m/item/proceduresand-data-requirements-changes-to-approved-vaccines-annex-4-trs-no-993

  28. World Health Organization. Guidelines on the stability evaluation of vaccines for useunder extended controlled temperature conditions. Technical Report Series. 2016; No. 999annex 5. Geneva: WHO; 2016 [acceso 09/08/2021]. Disponible en: https://www.who.int/publications/m/item/ectc-annex-5-trs-no-999

  29. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatoryexpectations. Technical Report Series. 2017; No. 1004 annex 9. Geneva: WHO; 2017[acceso 22/08/2021]. Disponible en: https://www.who.int/publications/m/item/WHOTRS-1004-web-annex-9

  30. Verez V. Vacuna contra el Haemophilus influenzae tipo b a partir de un antígenosintético. En: Rojas Ochoa, organizador. Vacunas. Cuba 1958-2008. La Habana: EditorialCiencias Médicas; 2011. p.138-42.

  31. Jacobo OL, Pérez R. Papel de las autoridades reguladoras de medicamentos en elaseguramiento de la calidad de las vacunas. En: Rojas Ochoa, organizador. Vacunas. Cuba1958-2008. La Habana: Editorial Ciencias Médicas; 2011. p. 271-80.

  32. CECMED. Registro de medicamentos y registro sanitario temporal. VAX-TET®. LaHabana: Minsap, CECMED; 2022 [acceso 20/03/2022]. Disponible en:https://servicio.cecmed.cu/sicecmed/libroRegistroMedicamento/ index

  33. Sotolongo F. Breve reseña histórica del Instituto Finlay. En: Rojas Ochoa, organizador.Vacunas. Cuba 1958-2008. 2011. La Habana: Editorial Ciencias Médicas. p. 143-45.

  34. Organización Mundial de la Salud. Inmunización y calidad de las vacunas. ResoluciónWHA45. 17 de la 45.ª Asamblea Mundial de la Salud. 1992. Ginebra: OMS. [acceso25/02/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/202846/WHA45_R17_spa.pdf?sequence=1&isAllowed=y

  35. Verez-Bencomo V, Fernández-Santana V, Hardy E, Toledo ME, Rodríguez MC,Heynngnez L, et al. The first human vaccine with a synthetic capsular polysaccharideantigen against Haemophilus influenzae type b. Science. 2004;305(23):522-5.




2020     |     www.medigraphic.com